Grantham Mayo Van Otterloo & Co. LLC Buys Shares of 547,812 Moderna, Inc. (NASDAQ:MRNA)

Grantham Mayo Van Otterloo & Co. LLC bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 547,812 shares of the company's stock, valued at approximately $22,778,000. Grantham Mayo Van Otterloo & Co. LLC owned approximately 0.14% of Moderna at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Moderna during the fourth quarter worth about $163,833,000. State Street Corp grew its holdings in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Pictet Asset Management Holding SA increased its position in shares of Moderna by 170.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after purchasing an additional 1,113,455 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Finally, Amundi lifted its position in shares of Moderna by 79.8% during the 4th quarter. Amundi now owns 1,206,273 shares of the company's stock worth $52,075,000 after purchasing an additional 535,273 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of analyst reports. JPMorgan Chase & Co. cut their price target on Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Friday, March 21st. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and cut their target price for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Bank of America lowered their price target on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. Barclays cut shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Leerink Partners lowered their target price on shares of Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $58.70.

Remove Ads

Moderna Trading Up 4.6 %

Shares of MRNA traded up $1.12 during mid-day trading on Friday, hitting $25.62. The company's stock had a trading volume of 5,637,920 shares, compared to its average volume of 7,145,033. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47. The firm has a market capitalization of $9.90 billion, a P/E ratio of -2.73 and a beta of 2.23. The firm has a 50-day simple moving average of $31.72 and a 200 day simple moving average of $41.27.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.